Orexo, a specialty pharmaceutical company, engages in the development and commercialization of drugs. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, an active substance zolpidem that is used for the treatment of short-term insomnia. The Company's development projects comprise OX382, oral formulation of buprenorphine; OX-CLI, a novel treatment of respiratory disorders, such as asthma and COPD; OX-MPI, for inflammatory related pain; and OX51, a sublingual formulation containing alfentanil for the prevention of acute pain during short surgical and diagnostic procedures.
|Employees (est.) (Nov 2018)||89||(+2%)|
Orexo has 366 Twitter Followers. The number of followers has increased 0.2% month over month and increased 4.7% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Orexo founded?
Orexo was founded in 1995.
How many employees does Orexo have?
Orexo has 89 employees.
Who are Orexo competitors?
Competitors of Orexo include CytomX Therapeutics, PharmScript and Lescarden.
Where is Orexo headquarters?
Orexo headquarters is located at 7E Rapsgatan, Uppsala.
Where are Orexo offices?
Orexo has an office in Uppsala.
How many offices does Orexo have?
Orexo has 1 office.